Edition:
United States

Sanofi SA (SNY)

SNY on New York Consolidated

43.74USD
23 Jan 2018
Change (% chg)

$0.54 (+1.25%)
Prev Close
$43.20
Open
$44.08
Day's High
$44.08
Day's Low
$43.48
Volume
3,066,059
Avg. Vol
1,336,818
52-wk High
$50.65
52-wk Low
$39.42

Latest Key Developments (Source: Significant Developments)

Regeneron And Sanofi Announce Positive Topline Pivotal Results For Pd-1 Antibody Cemiplimab In Advanced Cutaneous Squamous Cell Carcinoma
Wednesday, 13 Dec 2017 01:01am EST 

Regeneron Pharmaceuticals Inc ::REGENERON AND SANOFI ANNOUNCE POSITIVE TOPLINE PIVOTAL RESULTS FOR PD-1 ANTIBODY CEMIPLIMAB IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA.REGENERON PHARMACEUTICALS INC SAYS SAFETY PROFILE IN STUDY WAS GENERALLY CONSISTENT WITH APPROVED ANTI-PD-1 AGENTS..REGENERON PHARMACEUTICALS INC SAYS SUBMISSION TO EUROPEAN MEDICINES AGENCY (EMA) IS ALSO EXPECTED TO BE COMPLETED IN Q1 OF 2018.REGENERON PHARMACEUTICALS - ‍SUBMISSION TO U.S. FOOD AND DRUG ADMINISTRATION , WHICH HAS BEEN INITIATED AND IS EXPECTED TO BE COMPLETED IN Q1 OF 2018​.  Full Article

Sanofi Explores Combination Treatments For Multiple Myeloma In New Late-Stage Trials
Thursday, 7 Dec 2017 08:00am EST 

Dec 7 (Reuters) - Sanofi Sa ::SANOFI EXPLORES COMBINATION TREATMENTS FOR MULTIPLE MYELOMA IN NEW LATE-STAGE TRIALS.SANOFI - PHASE 3 TRIALS WILL EVALUATE ISATUXIMAB, AN ANTI-CD38 ANTIBODY, IN COMBINATION WITH OTHER CANCER TREATMENTS.  Full Article

EMA says Sanofi's dengue vaccine currently being reviewed, to take new data into account
Monday, 4 Dec 2017 01:20pm EST 

Dec 4 (Reuters) - Sanofi ::European Medicines Agency says in emailed statement Sanofi's dengue vaccine is currently being reviewed for a central marketing authorisation by the Agency's Committee for Medicinal Products for Human Use (CHMP).EMA says any emerging data will be taken into account during assessment of Dengvaxia.  Full Article

Sanofi Ends Development Of Clostridium Difficile Vaccine
Friday, 1 Dec 2017 04:01pm EST 

Dec 1 (Reuters) - Sanofi Sa ::SANOFI ENDS DEVELOPMENT OF CLOSTRIDIUM DIFFICILE VACCINE.SANOFI - IDMC FOR PHASE III CDIFFENSE CLINICAL TRIAL PROGRAM CONCLUDED THAT PROBABILITY THAT STUDY WILL MEET ITS PRIMARY OBJECTIVE IS LOW.SANOFI - HAS DECIDED TO DISCONTINUE CLINICAL DEVELOPMENT OF ITS EXPERIMENTAL CLOSTRIDIUM DIFFICILE VACCINE.SANOFI - SANOFI PASTEUR, VACCINES BUSINESS OF SANOFI RESPONSIBLE FOR PROGRAM, IS INFORMING INVESTIGATORS, REGULATORY AUTHORITIES & TRIAL ETHICS COMMITTEES.SANOFI - INVESTIGATORS ARE NOTIFYING STUDY VOLUNTEERS OF DECISION TO STOP PROGRAM.SANOFI - TO DISCONTINUE CLINICAL DEVELOPMENT OF EXPERIMENTAL CLOSTRIDIUM DIFFICILE VACCINE, TO FOCUS ON 6 VACCINE PROJECTS CURRENTLY IN DEVELOPMENT.SANOFI - ‍DATA FROM ALL VACCINATED VOLUNTEERS WILL CONTINUE TO BE ANALYZED FOR MORE INFORMATION & SHARED WITH SCIENTIFIC COMMUNITY​.  Full Article

Sanofi Ends Development Of Clostridium Difficile Vaccine
Friday, 1 Dec 2017 04:00pm EST 

Dec 1 (Reuters) - SANOFI ::REG-SANOFI ENDS DEVELOPMENT OF CLOSTRIDIUM DIFFICILE VACCINE.‍INDEPENDENT DATA MONITORING COMMITTEE (IDMC) FOR PHASE III CDIFFENSE CLINICAL TRIAL PROGRAM CONCLUDED THAT PROBABILITY THAT STUDY WILL MEET ITS PRIMARY OBJECTIVE IS LOW​.‍DECIDED TO DISCONTINUE CLINICAL DEVELOPMENT OF ITS EXPERIMENTAL CLOSTRIDIUM DIFFICILE VACCINE​.  Full Article

Aralez Announces Departure Of Chief Financial Officer
Thursday, 30 Nov 2017 05:00pm EST 

Nov 30 (Reuters) - Aralez Pharmaceuticals Inc ::ARALEZ ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER.ARALEZ PHARMACEUTICALS INC - ‍SCOTT J. CHARLES, CHIEF FINANCIAL OFFICER, IS LEAVING COMPANY​.ARALEZ PHARMACEUTICALS INC - MICHAEL KASETA WILL ASSUME POSITION OF INTERIM CHIEF FINANCIAL OFFICER.ARALEZ PHARMACEUTICALS INC - ‍ PRIOR TO JOINING ARALEZ, KASETA SERVED AS CFO OF SANOFI NORTH AMERICA, GLOBAL SERVICES​.  Full Article

Sanofi to book 100 mln eur charge in Q4, confirms 2017 business net income guidance
Wednesday, 29 Nov 2017 11:39am EST 

Nov 29 (Reuters) - Sanofi Sa ::SANOFI UPDATES INFORMATION ON DENGUE VACCINE.SANOFI - ‍NEW ANALYSIS OF LONG-TERM DENGVAXIA DATA FOUND DIFFERENCES IN VACCINE PERFORMANCE BASED ON PRIOR DENGUE INFECTION​.SANOFI SAYS IMPACT ON BUSINESS NET INCOME STILL UNDER ASSESSMENT BUT EXPECTED TO BE IN THE RANGE OF 100 MILLION EUR AFTER TAX.SANOFI SAYS WILL RECORD THE CHARGE REFLECTING DEPRECIATION OF INVENTORIES AS WELL AS ACCELERATED DEPRECIATION OF SOME TANGIBLE AND INTANGIBLE ASSETS IN ITS Q4 RESULTS.SANOFI SAYS CONFIRMS 2017 GUIDANCE.  Full Article

Teva Appoints Michael McClellan as CFO
Monday, 27 Nov 2017 09:00am EST 

Nov 27 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA ANNOUNCES NEW ORGANIZATION STRUCTURE AND LEADERSHIP CHANGES.TEVA PHARMACEUTICAL INDUSTRIES LTD - ‍COMMERCIAL BUSINESS WILL NO LONGER HAVE TWO SEPARATE GLOBAL GROUPS FOR GENERICS AND SPECIALTY MEDICINES​.TEVA PHARMACEUTICAL-‍FORMER GENERIC RESEARCH AND DEVELOPMENT, SPECIALTY RESEARCH AND DEVELOPMENT ORGANIZATIONS TO BE COMBINED INTO 1 GLOBAL GROUP WITH OVERALL RESPONSIBILITY FOR ALL RESEARCH AND DEVELOPMENT ACTIVITIES.TEVA - ‍AS A RESULT OF THE CHANGES, MICHAEL HAYDEN, ROB KOREMANS AND DIPANKAR BHATTACHARJEE WILL RETIRE FROM TEVA, EFFECTIVE DECEMBER 31​.TEVA PHARMACEUTICAL - ‍ COMMERCIAL BUSINESS WILL BE INTEGRATED INTO ONE COMMERCIAL ORGANIZATION​.TEVA - ‍MICHAEL MCCLELLAN APPOINTED EVP, CFO,WILL OVERSEE FINANCE GROUP, BUSINESS DEVELOPMENT, INVESTOR RELATIONS,INFORMATION TECHNOLOGY​.TEVA PHARMA - COMMERCIAL ‍STRUCTURE TO RELY ON 1 SUPPORTING ORGANIZATIONAL INFRASTRUCTURE INCLUDING FINANCE, LEGAL, HR, GLOBAL BRAND & COMMUNICATIONS​.TEVA PHARMACEUTICAL SAYS ‍ALREADY WORKING ON A DETAILED RESTRUCTURING PLAN FOR TEVA AND WILL SHARE IT IN MID-DECEMBER​.TEVA PHARMACEUTICAL INDUSTRIES LTD - ‍PRIOR TO JOINING TEVA, MICHAEL MCCLELLAN WAS U.S. CFO AT SANOFI​.  Full Article

Paulson & Co Inc dissolves share stake in Apple, Amazon and AIG
Tuesday, 14 Nov 2017 05:20pm EST 

Nov 14 (Reuters) - Paulson & Co Inc : :Paulson & Co Inc dissolves share stake in Apple Inc and Amazon.Com Inc - SEC filing.Paulson & Co Inc dissolves share stake in AIG - SEC filing.Paulson & Co Inc dissolves share stake in Glaxosmithkline Plc.Paulson & Co Inc dissolves share stake in Sanofi.Paulson & Co Inc cuts share stake in T-Mobile US Inc by 14.1 percent to 5.2 million shares.Paulson & Co Inc - Change in holdings are as of Sept 30, 2017 and compared with the previous quarter ended as of June 30, 2017.  Full Article

EMA grants Alnylam accelerated assessment of rare disease drug
Monday, 13 Nov 2017 07:30am EST 

Nov 13 (Reuters) - Alnylam Pharmaceuticals Inc :European Medicines Agency (EMA) grants Alnylam accelerated assessment of patisiran for patients with hereditary attr (hattr) amyloidosis.Alnylam Pharmaceuticals Inc - ‍company on track to submit marketing authorization application (maa) and new drug application (nda) at year-end 2017​.Alnylam Pharmaceuticals Inc - ‍alnylam intends to file a marketing authorization application (maa) in european union (eu) at year-end 2017​.Alnylam Pharmaceuticals Inc - ‍alnylam plans to file a new drug application for patisiran in united states by end of 2017​.Alnylam Pharmaceuticals Inc - ‍pending regulatory approvals, alnylam will commercialize patisiran in u.s., canada and western europe​.Alnylam Pharmaceuticals Inc - ‍pending regulatory approvals sanofi genzyme commercializing product in rest of world​.  Full Article

Celgene to buy Juno for $9 billion to boost cancer pipeline

Celgene Corp will pay $9 billion in cash to buy experimental cancer drugmaker Juno Therapeutics Inc, bulking up its developmental pipeline as it works to reduce reliance on its own cancer treatment Revlimid. | Video